Cannabis and Lipid Effects
Current evidence suggests that regular marijuana use is associated with decreased HDL cholesterol, but the effect on LDL cholesterol remains unclear and inconsistent. 1
Key Findings from Available Evidence
HDL Cholesterol (Decreased)
The most consistent finding across studies is that chronic cannabis smoking lowers HDL cholesterol levels. In a well-controlled study comparing chronic cannabis smokers to matched controls, HDL cholesterol was significantly lower in cannabis users (49 ± 14 vs. 55 ± 13 mg/dL; p = 0.02) 1. This represents a clinically meaningful reduction that could theoretically increase cardiovascular risk, as HDL cholesterol is inversely associated with cardiovascular events.
LDL Cholesterol (Inconsistent Evidence)
The evidence for LDL cholesterol changes is contradictory and inconclusive:
- The same controlled study found no significant difference in fasting LDL cholesterol levels between chronic cannabis smokers and non-smokers 1
- A 2019 review noted that observational studies show "variable" effects on plasma lipids, with some studies in specific populations suggesting "slightly more favorable lipoprotein profiles" in cannabis-exposed groups 2
- The review concluded that "widely variable findings...preclude any definitive conclusions" 2
Additional Metabolic Concerns
Beyond the lipid profile, chronic cannabis smoking was associated with:
- Increased visceral adiposity (18 ± 9% vs. 12 ± 5%; p = 0.004) 1
- Adipose tissue insulin resistance (lower percent FFA suppression during oral glucose tolerance testing) 1
- Higher carbohydrate intake despite no difference in total energy intake 1
Importantly, cannabis smokers did not show hepatic steatosis, systemic insulin insensitivity, impaired pancreatic β-cell function, or glucose intolerance 1.
Clinical Context and Interpretation
Why This Matters for Cardiovascular Risk
The reduction in HDL cholesterol is concerning because:
- Raising HDL cholesterol is associated with reduction in cardiovascular events 3
- Target HDL levels are >40 mg/dL in men and >50 mg/dL in women 4, 5
- The observed HDL levels in cannabis smokers (49 mg/dL) fall below optimal targets for women
Comparison to Tobacco Smoking
For context, tobacco smoking produces a more clearly atherogenic lipid profile with:
- Decreased HDL cholesterol 6, 7
- Increased LDL cholesterol 7
- Increased triglycerides 6, 7
- Increased total cholesterol 7
Cannabis appears to have a more limited but still unfavorable effect primarily on HDL cholesterol.
Clinical Recommendations
For patients who regularly use marijuana:
Screen lipid profiles annually (consistent with general diabetes and cardiovascular risk guidelines) 3, 5
If HDL cholesterol is low (<40 mg/dL in men, <50 mg/dL in women):
- Counsel on cannabis cessation as part of cardiovascular risk reduction
- Implement therapeutic lifestyle changes: increased physical activity, weight loss if overweight, dietary modification focusing on reducing saturated fat 4, 8
- Consider pharmacologic therapy with fibrates or niacin if lifestyle modifications are insufficient and other cardiovascular risk factors are present 3, 8
Monitor for visceral adiposity given the association with increased abdominal fat 1
Consider the overall cardiovascular context rather than focusing solely on isolated lipid changes, as cannabis has complex cardiovascular effects 2
Important Caveats
- Most evidence comes from observational studies with significant heterogeneity in cannabis exposure patterns (frequency, duration, route of administration)
- The clinical significance of modest HDL reductions in the absence of LDL increases remains uncertain
- No long-term cardiovascular outcome trials exist specifically examining cannabis use and cardiovascular events
- Effects may vary based on route of administration (smoked vs. oral) and frequency of use